Cargando…
Benefit and harm of lymphadenectomy in intermediate risk prostate cancer: comparison of five nomograms
BACKGROUND: Pelvic lymph node dissection (PLND) is recommended method for detecting prostate cancer (PCa) nodal metastases although associated with serious complications. In this study, we aimed to assess benefit/harm of routine PLND in intermediate risk PCa patients and to compare diagnostic yield...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10657577/ https://www.ncbi.nlm.nih.gov/pubmed/37980520 http://dx.doi.org/10.1186/s12894-023-01362-y |
_version_ | 1785148178121621504 |
---|---|
author | Lodeta, Branimir Baric, Hrvoje Hatz, Dominik Jozipovic, Danijel Augustin, Herbert |
author_facet | Lodeta, Branimir Baric, Hrvoje Hatz, Dominik Jozipovic, Danijel Augustin, Herbert |
author_sort | Lodeta, Branimir |
collection | PubMed |
description | BACKGROUND: Pelvic lymph node dissection (PLND) is recommended method for detecting prostate cancer (PCa) nodal metastases although associated with serious complications. In this study, we aimed to assess benefit/harm of routine PLND in intermediate risk PCa patients and to compare diagnostic yield of five different nomograms in predicting lymph node invasion (LNI). METHODS: Retrospective analysis of consecutive PCa patients with intermediate risk of biochemical recurrence who underwent open radical prostatectomy (RP) with bilateral PLND between January 2017 and December 2019 at our institution. Partin, 2012-Briganti, 2018-Briganti, Cagiannos and Memorial Sloan Kettering Cancer Center (MSKCC) values were calculated. To compare accuracy, sensitivity, specificity, and area under receiver-operating curve (AUC) were calculated and then optimal cutoff values were estimated, analyses repeated and compared. To assess benefit and harm of PLND, relative risk (RR) and number need to treat (NNT) with LNI and complications set as outcome were calculated. RESULTS: Total 309 subjects. Average age 62.2 years, average PSA 7.2 ng/mL; 18 (5.8%) had LNI; 88 (28.5%) suffered Clavien-Dindo grade 3–5 complication. AUC for predicting LNI: 0.729 for 2012-Briganti, 0.660 for MSKCC, 0.521 for 2018-Briganti, 0.486 for Cagiannos, and 0.424 for Partin. None of pairwise AUC comparisons based on default and newly established cutoff values were statistically significant. Lowest NNT was for Partin and Cagiannos with default cutoff (≥ 5%). Risks of serious complications between higher/lower than cutoff values were non-significant across nomograms. CONCLUSIONS: 2012-Briganti nomogram outperforms, although not significantly, MSKCC, 2018-Briganti, Cagiannos, and Partin nomograms in classifying LNI in intermediate risk PCa patients. Routine PLND in these patients should be avoided, due to high rate and severity of complications. |
format | Online Article Text |
id | pubmed-10657577 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-106575772023-11-18 Benefit and harm of lymphadenectomy in intermediate risk prostate cancer: comparison of five nomograms Lodeta, Branimir Baric, Hrvoje Hatz, Dominik Jozipovic, Danijel Augustin, Herbert BMC Urol Research BACKGROUND: Pelvic lymph node dissection (PLND) is recommended method for detecting prostate cancer (PCa) nodal metastases although associated with serious complications. In this study, we aimed to assess benefit/harm of routine PLND in intermediate risk PCa patients and to compare diagnostic yield of five different nomograms in predicting lymph node invasion (LNI). METHODS: Retrospective analysis of consecutive PCa patients with intermediate risk of biochemical recurrence who underwent open radical prostatectomy (RP) with bilateral PLND between January 2017 and December 2019 at our institution. Partin, 2012-Briganti, 2018-Briganti, Cagiannos and Memorial Sloan Kettering Cancer Center (MSKCC) values were calculated. To compare accuracy, sensitivity, specificity, and area under receiver-operating curve (AUC) were calculated and then optimal cutoff values were estimated, analyses repeated and compared. To assess benefit and harm of PLND, relative risk (RR) and number need to treat (NNT) with LNI and complications set as outcome were calculated. RESULTS: Total 309 subjects. Average age 62.2 years, average PSA 7.2 ng/mL; 18 (5.8%) had LNI; 88 (28.5%) suffered Clavien-Dindo grade 3–5 complication. AUC for predicting LNI: 0.729 for 2012-Briganti, 0.660 for MSKCC, 0.521 for 2018-Briganti, 0.486 for Cagiannos, and 0.424 for Partin. None of pairwise AUC comparisons based on default and newly established cutoff values were statistically significant. Lowest NNT was for Partin and Cagiannos with default cutoff (≥ 5%). Risks of serious complications between higher/lower than cutoff values were non-significant across nomograms. CONCLUSIONS: 2012-Briganti nomogram outperforms, although not significantly, MSKCC, 2018-Briganti, Cagiannos, and Partin nomograms in classifying LNI in intermediate risk PCa patients. Routine PLND in these patients should be avoided, due to high rate and severity of complications. BioMed Central 2023-11-18 /pmc/articles/PMC10657577/ /pubmed/37980520 http://dx.doi.org/10.1186/s12894-023-01362-y Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Lodeta, Branimir Baric, Hrvoje Hatz, Dominik Jozipovic, Danijel Augustin, Herbert Benefit and harm of lymphadenectomy in intermediate risk prostate cancer: comparison of five nomograms |
title | Benefit and harm of lymphadenectomy in intermediate risk prostate cancer: comparison of five nomograms |
title_full | Benefit and harm of lymphadenectomy in intermediate risk prostate cancer: comparison of five nomograms |
title_fullStr | Benefit and harm of lymphadenectomy in intermediate risk prostate cancer: comparison of five nomograms |
title_full_unstemmed | Benefit and harm of lymphadenectomy in intermediate risk prostate cancer: comparison of five nomograms |
title_short | Benefit and harm of lymphadenectomy in intermediate risk prostate cancer: comparison of five nomograms |
title_sort | benefit and harm of lymphadenectomy in intermediate risk prostate cancer: comparison of five nomograms |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10657577/ https://www.ncbi.nlm.nih.gov/pubmed/37980520 http://dx.doi.org/10.1186/s12894-023-01362-y |
work_keys_str_mv | AT lodetabranimir benefitandharmoflymphadenectomyinintermediateriskprostatecancercomparisonoffivenomograms AT barichrvoje benefitandharmoflymphadenectomyinintermediateriskprostatecancercomparisonoffivenomograms AT hatzdominik benefitandharmoflymphadenectomyinintermediateriskprostatecancercomparisonoffivenomograms AT jozipovicdanijel benefitandharmoflymphadenectomyinintermediateriskprostatecancercomparisonoffivenomograms AT augustinherbert benefitandharmoflymphadenectomyinintermediateriskprostatecancercomparisonoffivenomograms |